In a recent Discoveries in Health Policy blog post, Bruce Quinn called the Food and Drug Administration’s June 12 press release on tools to fight antimicrobial-resistant infections a “major land-grab on new paradigms that CMS might float … for drug payments.”
Quinn says FDA Commissioner Scott Gottlieb in the release “proposed an entirely novel payment paradigm,” and that the agency is currently in talks with other agencies, including the Centers for Medicare and Medicaid Services.
“In brief, the proposal is that certain rare antibiotics would be licensed on a per click annual basis by hospitals rather than conventional payment,” Quinn writes. “Since only a small fraction of all infectious disease patients are FFS Medicare patients, the plan would have to be nationalized across Medicaid and other payers to be impactful for early investors.”
To read the FDA press release, click here.